Viatris To Bring In Plenty Of Brand Knowledge With New CEO Smith
Former Celgene Exec Also Brings Deals Experience
Executive Summary
Only three months after joining Viatris’ board of directors, Scott Smith, famed for spearheading Celgene’s successful and lucrative Inflammation and Immunology division, has been announced as the company’s new CEO, beginning 1 April.
You may also be interested in...
Finance Watch: BioAtla, Virios And Scopus Launch Latest US IPOs
Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.
Pfizer To Merge Off-Patent Business With Mylan
Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.
Krka Talks Russia, Ukraine, One Year After Conflict Began
Slovenia’s Krka enjoyed a solid year for its dominant Prescription Pharmaceuticals business, with sales climbing by 7% on the back of growth for all six of its geographic business units.